
Building a clinical-grade monitoring platform takes more than a good idea. It takes funding, science, clinical rigor, manufacturing discipline, and sound counsel. Senphonix has assembled all of it, and that network is one of the clearest signals of where this is headed.
In addition to founder funding and a pre-seed SAFE, federal and state programs have helped to fund the development of SleeveSense™, a strong external validation of both the science and the need.








“Burnout comes from constantly choosing which task to delay. Automation reduces those tradeoffs, and that matters for retention.”
“We are planning for a future where staffing shortages are normal. Solutions that assume things go back to the way they were are not realistic.”
SleeveSense™ will be available upon FDA clearance, which is expected in 2027.
Senphonix is a Delaware C-Corp., with offices in Minnesota and Arizona. For more information, contact us at info@senphonix.com or 612-913-0607; or follow us on LinkedIn. Copyright © 2026 Senphonix, Inc. - All Rights Reserved. Logos and trademarks are the property of their respective owners. All quotes herein are drawn from anonymous responses to two MarketWise Advising ("MarketWise") national studies, commissioned by Senphonix; some quotes were lightly edited for brevity.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.